Mesoblast (MESO) Cash from Operations Growth (3y) (2019 - 2023)
Mesoblast (MESO) Cash from Operations Growth (3y) (2019 - 2023) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -5.07% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 33.08% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 16.64% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -7.60% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Mesoblast | 2.08 Bn | 1.95 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | -6.08% |
| Mar 31, 2023 | 6.52% |
| Dec 31, 2022 | -131.28% |
| Sep 30, 2022 | 2.80% |
| Jun 30, 2022 | 10.04% |
| Mar 31, 2022 | 9.95% |
| Dec 31, 2021 | -122.26% |
| Sep 30, 2021 | 2.35% |
| Jun 30, 2021 | 2.14% |
| Mar 31, 2021 | -7.67% |
| Dec 31, 2020 | -27.18% |
| Sep 30, 2020 | -11.43% |
| Jun 30, 2020 | 16.52% |
| Mar 31, 2020 | 8.15% |
| Dec 31, 2019 | 62.66% |
| Sep 30, 2019 | 9.26% |
| Jun 30, 2019 | -1.80% |
| Mar 31, 2019 | 1.30% |